From: Management of anal cancer patients – a pattern of care analysis in German-speaking countries
University (A) vs. Non-university Clinic (B) vs. out-patient practice (C) | p-Value | |||
---|---|---|---|---|
Total no of answers: 101 | A | B | C | |
Dose to GTV T1/T2 Tumors | ||||
50–50.4 Gy | 4 (20) | 7 (19) | 4 (9) | |
54–55.8 Gy | 10 (50) | 19 (53) | 29 (66) | |
59.4 Gy | 5 (25) | 10 (28) | 10 (23) | |
> 60 Gy | 1 (5) | 0 (0) | 1 (2) | 0.60 |
Dose to GTV T3/T4 tumors | ||||
54–55.8 Gy | 6 (30) | 2 (6) | 5 (11) | |
59.4 Gy | 11 (55) | 30 (83) | 35 (78) | |
> 60 Gy | 3 (15) | 4 (11) | 5 (11) | 0.1 |
Dose to elective lymph nodes | ||||
30.6 Gy | 0 (0) | 2 (6) | 1 (2) | |
36 Gy | 4 (20) | 2 (6) | 9 (20) | |
45 Gy | 13 (65) | 22 (61) | 29 (64) | |
50.4 Gy | 3 (15) | 10 (27) | 6 (13) | 0.31 |
Dose to involved lymph nodes | ||||
36 Gy | 1 (5) | 0 (0) | 0 (0) | |
45 Gy | 1 (5) | 1 (3) | 3 (7) | |
50.4 Gy | 7 (35) | 7 (19) | 18 (40) | |
54–55.8 Gy | 9 (45) | 25 (69) | 22 (49) | |
59.4 Gy | 2 (10) | 3 (8) | 2 (4) | 0.32 |